ReviewJournal of neurochemistry2026
The Enteric Nervous System as a Mediator of Microbiota-Gut-Brain Interactions in Parkinson's Disease.
Review in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preface to the Special Issue: "Microbiota and Gut-Brain Axis".Journal of neurochemistry · 2026Article
- The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions.Microorganisms · 2026Review
- The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders-From Mechanisms to Precision Therapeutics.Veterinary sciences · 2026Review
- The Enteric Nervous System as a Mediator of Microbiota-Gut-Brain Interactions in Parkinson's Disease.Journal of neurochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder in which gastrointestinal dysfunction is highly prevalent and often precedes motor symptoms. Although research on gut microbiota alterations in PD has expanded rapidly, inconsistent findings and the absence of a reproducible microbial signature reveal the limitations of a microbiota-centered view. The enteric nervous system (ENS), the intrinsic neural network of the gut, has been comparatively overlooked and remains underexplored, yet mounting evidence indicates that it undergoes profound alterations in PD. Pathological changes in enteric neurons and glial cells, including α-synuclein accumulation, disrupted neurotransmission, impaired epithelial barrier regulation, and neuroinflammation, not only contribute to gastrointestinal dysfunction but may also drive disease propagation along the gut-brain axis. In parallel, PD-related dysbiosis alters microbial metabolites and immune signaling, disrupting ENS physiology. This review reframes PD gut pathology by emphasizing the ENS as a central mediator of microbiota-brain communication. We highlight potential key pathways underlying this crosstalk, including short-chain fatty acids (SCFAs), Toll-like receptor (TLR) signaling, and serotonergic circuits, which normally sustain ENS function but, in the context of PD, contribute to barrier impairment, neuroinflammation, and neuronal alterations. By integrating evidence from human studies and experimental models, we argue that investigating ENS-microbiota interactions provides a more comprehensive perspective on PD pathophysiology and may guide the identification of novel biomarkers and therapeutic approaches capable of addressing both gastrointestinal and neurological manifestations of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.